# A Clinical Trial of BP1002 in Patients With Advanced Lymphoid Malignancies

> **NCT04072458** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Bio-Path Holdings, Inc.** · enrollment: 30 (estimated)

## Conditions studied

- Mantle Cell Lymphoma
- Peripheral T-cell Lymphoma (PTCL)
- Cutaneous T-cell Lymphoma (CTCL)
- Chronic Lymphocytic Leukemia (CLL)
- Small Lymphocytic Lymphoma (SLL)
- Follicular Lymphoma
- Marginal Zone Lymphoma
- Hodgkin Lymphoma
- Waldenstrom Macroglobulinemia
- DLBCL

## Interventions

- **DRUG:** L-Bcl-2 antisense oligonucleotide

## Key facts

- **NCT ID:** NCT04072458
- **Lead sponsor:** Bio-Path Holdings, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2020-11-05
- **Primary completion:** 2025-04
- **Final completion:** 2025-04
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2025-02-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04072458

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04072458, "A Clinical Trial of BP1002 in Patients With Advanced Lymphoid Malignancies". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04072458. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*